Document is current
Any future updates will be listed below
-
Authors
Alecu, Julian E.
Sigutova, Veronika
Brazdis, Razvan-Marius
Lörentz, Sandra
Bogiongko, Marios Evangelos
Nursaitova, Anara
Regensburger, Martin
Roybon, Laurent
Galler, Kerstin M.
Wrasidlo, Wolfgang
Winner, Beate
Prots, Iryna
-
Funding
Funding for this research was provided by:
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 10 May 2024
Accepted: 10 January 2025
First Online: 28 January 2025
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki. Human iPSCs derived from human dermal fibroblasts were obtained from the stem cell unit of the Friedrich-Alexander University Erlangen-Nürnberg. Written informed consent was received from voluntary donors of skin biopsies prior to inclusion in the study at the Movement Disorder Clinic at the Department of Molecular Neurology, University Hospital Erlangen. All experiments using human iPSC-derived cells were conducted in accordance with the Institutional Review Board approval (Nr. 259_17B), as well as national and European Union directives. The iPSC line CSC-1 was generated from fibroblasts obtained with informed consent and after ethical committee approval at the Parkinson Institute in Milan. The permit for reprogramming of CSC-1 was delivered by the Swedish Work Environment Authority (Arbetsmiljöverket, reg.-no.: 20200 − 3211).
: WW is a cofounder of Neuropore Therapies, Inc. (San Diego, CA, USA). The other authors declare to have no conflict of interest.
